BlueForge Alliance and Palantir Launch Warp Speed for Warships to Digitally Transform the U.S. Maritime Industrial Base
Powered by Palantir's proven Warp Speed manufacturing operating system, Warp Speed for Warships is designed to accelerate shipbuilding modernization and readiness by digitally taking the first steps to better connect the network of shipbuilders, suppliers, and critical partners responsible for building and sustaining the Navy's fleet.
As shipbuilders and suppliers across the maritime industrial base MIB work to meet unprecedented production demands and evolving national security priorities, this partnership combines deep industrial insight and field-tested technology to unlock new levels of performance and coordination through a digitally connected manufacturing ecosystem.
Built on the backbone of Palantir's platform configured as Foundry — a secure enterprise operating system that integrates data, logic, models, and decision-making tools into a single operational picture— Warp Speed for Warships enables real-time collaboration and insight across the MIB. When paired with BFA's embedded manufacturing and MIB supply chain expertise, Warp Speed for Warships accelerates delivery, reduces risk, and creates a connected system engineered to meet the urgent demand of the Navy and the nation.
'Our strategic partnership with Palantir is about moving with urgency and precision — equipping America's industrial base with the tools it needs to meet unprecedented demand,' said Kiley Wren, BlueForge Alliance co-founder and co-chief executive officer. 'In Palantir, we've found a mission-aligned partner capable of turning complexity into clarity, and data into action. With the Warp Speed for Warships program, together with our nation's shipbuilders and suppliers, we're helping the Navy deliver the modern digital infrastructure required to scale production, drive resilience, and ensure our nation's shipbuilding enterprise is prepared for what lies ahead.'
Initiatives like Warp Speed for Warships and collaborative national strategic partnerships represent a renewed model of public-private collaboration, where BFA's role as a trusted integrator supporting the Navy's efforts to strengthen the MIB is paired with Palantir's advanced data platform to rapidly convert integrated information into action.
'Warp Speed for Warships is a critical effort to ensure the Navy has the digital tools to maintain maritime superiority and deter conflict. The combination of BlueForge Alliance's trusted role in the shipbuilding ecosystem and Palantir's Warp Speed software will give shipbuilders the modern tools they need to reestablish command of the seas and keep the peace,' said Mike Gallagher, Head of Defense at Palantir Technologies.
About BlueForge Alliance
BlueForge Alliance is a nonprofit, mission-driven partner accelerating the revitalization of the defense industrial base through non-traditional approaches that deliver speed, access and scale. As an unbiased convening authority, we unite government, industry, and academia through a whole-of-nation, whole-of-government approach to address systemic challenges with collaborative, transparent, and innovative solutions. BFA is headquartered in Bryan/College Station, Texas with its Maritime Practice based in Washington, D.C. For more information, visit www.BlueForgeAlliance.us.
About Palantir Technologies Inc.
Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.
About the Maritime Industrial Base Program
The Navy's Maritime Industrial Base Program was established to develop, implement, and execute a plan to stabilize, enhance, and grow the maritime industrial base by addressing challenges to industrial base capacity, capability, and workforce. For more information, visit https://www.secnav.navy.mil/rda/mib/Pages/default.aspx.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir's expectations regarding the amount and the terms of the contract and the expected benefits of Palantir's software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond Palantir's control. These risks and uncertainties include the ability to meet the unique needs of customers; the failure of Palantir's platforms to satisfy customers or perform as desired; the frequency or severity of any software and implementation errors; Palantir's platforms' reliability; and customers' ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings Palantir makes with the Securities and Exchange Commission from time to time. Except as required by law, Palantir does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures and generalized epilepsy. The stock initially surged on the news, but then reversed course and is currently trading down approximately 9%. The central nervous system (CNS) disorders-focused company said the topline results from the Phase 2 RADIANT study included data from 37 patients.'These findings build on our earlier clinical data showing a differentiated profile for vormatrigine as a fast-acting, no-titration, once-daily oral drug with no requirement to be taken with food, and a favorable DDI profile, all of which are unseen in ASMs currently in the market or in development,' said Marcio Souza, president and CEO of Praxis. In an investor presentation on the company website, Praxis noted that the trial showed a median seizure reduction of around 56.3%, with 60% of the patients achieving at least a 50% reduction in seizures. This positive outcome has encouraged the company to move forward with a Phase 2/3 trial, even though 23% of patients discontinued the study. 54% of patients achieved at least a 50% seizure reduction threshold in Week 1 and 67% in Week 8. In the last month of the dataset, 22% of the patients experienced a 100% reduction in seizure frequency. The company added that most adverse events were mild to moderate and transient. All severe and serious adverse events (AEs) were recovered and resolved. The investor presentation noted that the investigators had the option to reduce the dose of the background medication to manage AEs; when done (6 patients), no discontinuation was observed. The company said it is on track to complete the pivotal, 12-week POWER1 study in the fourth quarter of 2025 and, based on the results from RADIANT, it expects to initiate the POWER2 study shortly. On Monday, the company reported cash and investments of approximately $447 million and maintains a cash runway into 2028. In July, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Praxis Precision's relutrigine, a sodium channel functional state modulator for pediatric use for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The EMBOLD cohort 2 pivotal trial is on track for topline results in the first half of 2026, with NDA filing to follow. Praxis has recently initiated the EMERALD study investigating relutrigine broadly in DEEs. Price Action: PRAX stock is trading lower by 9.51% to $48.95 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
16 minutes ago
- Yahoo
Palantir is set to report second quarter earnings after announcing $10 billion US Army deal
Palantir (PLTR) was set to report quarterly earnings Monday after the bell, with Wall Street expecting another period of double-digit growth for the defense tech firm. Wall Street analysts tracked by Bloomberg expect the company to report second quarter adjusted earnings per share of $0.14, up from $0.09 the prior year. They expect revenue to hit $939.25 billion, up roughly 39% from last year, according to Bloomberg data. 'Expectations for Palantir headed into earnings are as high as ever,' DA Davidson analyst Gil Luria told Yahoo Finance in an email. 'The company has easily exceeded expectations for several recent quarters and appears to have more momentum than any other publicly traded software company.' Read more: Live coverage of corporate earnings Palantir sells its artificial intelligence software to businesses and governments in the US and abroad. Its tech does everything from supply chain analysis to surveillance and identifying military targets, the latter of which has drawn backlash from human rights advocates. In May, Palantir stock fell 12% the day after its first quarter results as investors scrutinized the company's valuation and declining sales in its international commercial business, which sells software to businesses abroad, even as its first quarter revenue blew past Wall Street's forecasts. While analysts expect revenue from sales to governments and US businesses to continue soaring in the second quarter, they see sales in its international commercial segment declining slightly to about $147.1 billion from $148 billion last year. Boosting optimism for the future of its revenue from the US government, Palantir announced Thursday that it had inked a deal with the US Army worth up to $10 billion over the next 10 years. Wedbush analyst Dan Ives, a notable Palantir bull, said the deal is 'one of the largest ever DOD [Department of Defense] software contracts in US history.' 'We believe this deal represents an additional tailwind for PLTR with AI initiatives across the US government accelerating with AI a strategic focus on the federal front and Palantir in the sweet spot to benefit from a tidal wave of federal spending on AI,' Ives wrote in a note to investors Friday. Overall, Wall Street remains mixed on Palantir stock, however. Ives is one of 10 analysts who hold a Buy rating on shares, while 16 have a Hold rating, and five recommend selling the stock, according to Bloomberg data. Bears remain concerned that Palantir is overvalued. Palantir stock currently trades at levels 24 times the historical market multiple of the S&P 500 (^GSPC). Shares of Palantir are up more than 105% this year, relative to the S&P 500's 6.3% gain, and the stock has far outperformed the "Magnificent Seven" Big Tech stocks in 2025. 'We cannot rationalize why Palantir is the most expensive name in our software coverage,' RBC Capital Markets analyst Rishi Jaluria wrote in a note to clients Wednesday. 'Absent a substantial beat-and-raise quarter elevating the NT [near term] growth trajectory, valuation seems unsustainable.' A 'beat and raise' refers to a company's earnings surpassing Wall Street's expectations and raising its financial outlook for the upcoming Bratton is a reporter for Yahoo Finance. Follow her on Bluesky @ Email her at
Yahoo
20 minutes ago
- Yahoo
Amazon.com Second Quarter 2025 Earnings: Beats Expectations
(NASDAQ:AMZN) Second Quarter 2025 Results Key Financial Results Revenue: US$167.7b (up 13% from 2Q 2024). Net income: US$18.2b (up 35% from 2Q 2024). Profit margin: 11% (up from 9.1% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$1.71 (up from US$1.29 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) also surpassed analyst estimates by 26%. Looking ahead, revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Multiline Retail industry in the US. Performance of the American Multiline Retail industry. The company's shares are down 7.7% from a week ago. Risk Analysis It is worth noting though that we have found 1 warning sign for that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
